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ABSTRACT
Anti-Cancer effects of oleocanthal and extra virgin olive oil
By
Limor Goren
Advisor: David Foster

Oleocanthal is a phenolic compound found in varying concentrations in extra virgin olive
oil. Oleocanthal has been shown to be active physiologically, benefiting several
diseased states by conferring anti-inflammatory and neuroprotective benefits. Recently,
we and other groups have demonstrated its specific and selective toxicity toward cancer
cells; however, the mechanism leading to cancer cell death is still disputed. The current
study demonstrates that oleocanthal induced damage to cancer cells’ lysosomes
leading to cellular toxicity in vitro. Non-cancer cells were significantly less affected.
Lysosomal membrane permeabilization following oleocanthal treatment in various cell
lines was assayed via three complementary methods. Additionally, we found
oleocanthal treatment reduced tumor burden and extended lifespan of mice engineered
to develop pancreatic neuroendocrine tumors. Finally, following-up on numerous
correlative studies demonstrating consumption of olive oil reduces cancer incidence and
morbidity, we observed that extra virgin olive oils naturally rich in oleocanthal sharply
reduced cancer cell viability and induced lysosomal membrane permeabilization while
oleocanthal-poor oils did not. Our results are especially encouraging since tumor cells
often have larger and more numerous lysosomes, making them more vulnerable to
lysosomotropic agents such as oleocanthal.
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CHAPTER 1: INTRODUCTION
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The Mediterranean diet and olive oil
Olive oil has been consumed by humans for millennia and is frequently associated with
health-related properties. The Mediterranean diet and olive oil consumption in particular
are correlated with lower cancer incidence and mortality (1-3). A meta analyses of
nineteen observational studies performed between 1990 and 2011 that included
approximately 35,000 individuals found that olive oil intake is inversely related to cancer
prevalence (4) (Figure 1.1). More recently, a randomized trial found that women who
adhered to a Mediterranean diet supplemented with extra virgin olive oil (EVOO) had
62% less invasive breast cancer incidence than a control group that was advised to
restrict dietary fats (5). The study, called PREDIMED was a 1:1:1 randomized, singleblind, controlled field trial conducted in Spain over a period of 6 years with over 4000
participants (Figure 1.2)

The PREDIMED trial, and other studies, however, did not distinguish between
the protective effects of EVOO’s triglycerides and its phenolic components.
Furthermore, to the best of our knowledge, no controlled study tested the effect of high
phenolic EVOO on cancer.

2

Figure 1.1: Association between olive oil intake and cancer development. Forest plot of
studies that evaluated the association between olive oil intake and cancer development. Data
are presented as log Odds Ratios and the corresponding 95%CI. Source: (4)
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Figure 1.2: PREDIMED trial results. Incidence of invasive breast cancer and corresponding
hazard ratios among the three interventional groups. Source (5)

Oleocanthal
(-)-Oleocanthal (Oleocanthal, or OC) (Figure 1.3), also known as deacetoxy-ligstroside
aglycon, was first identified as a minor phenolic compound in the fruit of the olive tree by
Motedoro et al. in 1993 (6). A few years later, it was reported to be the primary agent
that conveys strong stinging sensation at the back of the throat when ingesting certain
EVOOs (7). In 2005, Beauchamp and colleagues published the first paper to refer to
this compound as Oleocanthal [Oleo - for oil, Canth – Greek for stinging or literally
prickly (named for the throat irritation caused by oleocanthal), and Al – for the two
aldehyde groups that are believed to be responsible for oleocanthal’s reactivity] (8).
Beauchamp and colleagues also identified oleocanthal as a potent inhibitor of
cyclooxygenase enzymes, conferring anti-inflammatory activity that was more potent
4

than ibuprofen (8). Since this pioneering oleocanthal paper was published, several
groups looked at its medicinal neuroprotective properties. Pitt et al. observed that low
doses of oleocanthal altered Alzheimer’s-associated amyloid-β oligomers (9), and Li et
al reported that oleocanthal inhibited tau fibrillization (10). In 2018, Batarseh et al.
reported that high-oleocanthal EVOO reduced amyloid-β load and related toxicity in a
mouse model of Alzheimer's disease (11).

Oleocanthal and cancer
Since oleocanthal inhibits cyclooxygenase enzymes that mediate inflammation, which is
associated with cancer initiation and progression, there was increasing interest in
studying the anti-cancer properties of oleocanthal. The first reports of oleocanthal
attenuating tumorigenicity were in 2011. Elnagar et al. (12) demonstrated oleocanthal’s
ability to prevent cell migration in a metastatic model for the breast carcinoma cell line
MDA-MB-231. Khanal et al.(13) showed that oleocanthal inhibits phorbol ester-induced
cell transformation in murine JB6 Cl41 cells. Additionally, the authors showed that
oleocanthal inhibits proliferation and the ability to form colonies formation in soft agar of
HT-29 colon cancer cells. Other reports illustrated the anti-proliferative activity of
oleocanthal using various cancer cell lines – including breast carcinoma (14), multiple
myeloma (15), hepatocellular carcinoma (16), melanoma (17), and prostate cancer (12).
The proposed mechanisms for oleocanthal activity differ among the different research
groups (Figure 1.3). El Sayed and colleagues published several papers illustrating that
oleocanthal acts a c-Met inhibitor (12, 14, 18). c-Met is a receptor tyrosine kinase that is
activated by hepatocyte growth factor. c-Met acts upstream of both the PI3K and the
MAPK pathways. The El Sayed group demonstrated oleocanthal inhibitory effects on c5

Met downstream targets when cells were stimulated with hepatocyte growth factor. In
their studies, the mode of death was apoptotic as evident by the induction of cleaved
caspase-3 and cleaved PARP. Pei et al. reported that oleocanthal inhibits growth and
metastasis of hepatocellular carcinoma by blocking activation of the transcription factor
STAT3 (16). Interestingly, one of the canonical ways in which STAT3 is activated is via
receptor tyrosine kinases, including c-Met. Yet the upstream initiating event that
promotes cancer cell death remains uncertain. Other cellular responses to oleocanthal
treatment in cancer cells that were reported recently include inhibition of MIP-1α
expression and secretion, (15), activation of AMPK (13), downregulation of AKT and
ERK 1/2 (17), downregulation of TRPC6 expression (19), and ROS generation (20).
Whereas our group previously reported that oleocanthal induces cancer cell death via
lysosomal membrane permeabilization (LMP) (21), other mechanisms for cancer cell
death – notably apoptosis – in response to oleocanthal have been reported (13-18, 20).

6

Figure 1.3: Structure of Oleocanthal and its previously described anti-cancerous targets.
Titles in blue represent proteins or processes affected, descriptions in red are the types of
cancers in which the studies were done. Numbers in parentheses are references in the main
text.

Lysosomal membrane permeabilization
Most of the published data about oleocanthal’s toxicity is specific to cancer cells, while
the same reports illustrate that normal human cells are only minimally affected (14-17,
21, 22). This phenomenon can be explained by oleocanthal’s effect on lysosomal
membranes stability.
Different forms of stress can induce LMP (Figure 1.4), which causes release of
intra-lysosomal enzymes to the cytoplasm – resulting in lysosome-dependent cell death
(23). This newly appreciated cell-death mechanism is gaining interest, since
7

transformed cells are often characterized by a large increase to their lysosomal
compartment and are strongly dependent on lysosomal function (24).

Figure 1.4: Inducers of LMP. Agents such as cationic amphiphilic drugs can induce LMP and
the translocation to the cytoplasm of lysosomal hydrolases (e.g. cathepsins). ROS can pass
through the lysosomal membrane and, in the presence of free iron, catalyze Fenton reactions to
produce highly toxic intermediates that damage lysosomal proteins, including Hsp70.
Lysosomotropic detergents and some antibiotics can enter lysosomes and destabilize the
lysosomal membrane, a process exacerbated by photodamage. Calpains, activated by
increases in calcium, target several lysosomal proteins, including LAMP2 and Hsp70. This
process is enhanced by Hsp70 oxidation caused by intralysosomal Fenton reactions. LMP is
also induced by other agents, including bacterial and viral products, silica crystals, and
nanoparticles. Source: (25)
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Lysosomes contain over 50 different hydrolases, and many of these are upregulated and utilized by cancer cells, often in secreted forms, for purposes of invasion,
angiogenesis, and progression (26, 27). The increased reliance on lysosomal processes
might also represent an Achilles’ heel for cancer. As Christian DeDuve, the discovered
of lysosomes, noted – the high concentration of degradative enzymes in lysosomes
make them in essence “suicide bags” (28). Lysosomes in transformed cells are more
susceptible to rupture, causing release of hydrolases such as cathepsin (generic name
for lysosomal proteases) into the cytosol (29). Depending upon the degree of LMP, both
apoptotic and non-apoptotic death can be observed (23, 30). Low levels of LMP injure
cells and trigger apoptotic death mechanisms, whereas high levels of LMP kill cells
rapidly and directly as a form of necrosis (figure 1.5).

Figure 1.5: Lysosome dependent cell death mechanisms. Lethal pathways activated as a
result of lysosomal membrane permeabilization. A variety of different effector molecules can
9

trigger a range of distinct modalities of cell death. The dominant pathway depends on the
intensity of LMP, on the expression level of lysosomal hydrolases, the cytosolic concentrations
of cathepsin inhibitors, the functional state of mitochondria, the concentration of caspases and
their antagonists, as well as multiple additional factors. Source: (30)

In this body of work, we demonstrate oleocanthal’s ability to induce severe LMP
in a variety of cancer cells lines, leading to rapid necrotic cell death in vitro and
shrinkage of tumors and extension of lifespan in an in vivo mouse model for pancreatic
neuroendocrine tumors (PNETs). Strikingly, we were also able to replicate the beneficial
effects of purified oleocanthal by treating cells with EVOOs that naturally contain high
levels of oleocanthal.

10

CHAPTER 2: RESULTS
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Oleocanthal induces rapid necrotic cell death in a variety of cancer cells
As we and other groups have previously reported, oleocanthal is toxic to many cancer
cells and causes rapid and extreme loss of cell viability without killing healthy cells (14,
16, 21). We treated a panel of cancer cells and normal human cells with 20 µM
oleocanthal, and as expected, saw a sharp loss in viability within 24 hours among the
cancer cells (MDA-MB-231 human breast cancer cells, PC3 human prostate cancer cell
lines, and N134 murine PNET cancer cells) while the non-cancerous cells (MCF10A
human breast epithelial cells, HEK293T human kidney cells, and BJ-hTERT human
fibroblast cells) were less affected by oleocanthal treatment (Figure 2.1.A). Phenotypic
changes were observed as rapidly as one hour post treatment when cells started to
round up and detach from the cell culture dishes. Moreover, loss in cell viability was
induced in PC3 cells by a brief 60 min treatment of oleocanthal followed by removal of
the treatment media (Figure 2.1.B) – indicating that the cell death induced by
oleocanthal is rapid. We previously reported that oleocanthal-induced cell death is due
to a necrotic mechanism, whereas other groups have reported the mechanism of death
to be apoptotic . The particular cell death modality could indeed be concentration
dependent as even in our hands, low concentration of oleocanthal result in some
apoptotic markers such as accumulation of cleaved PARP. To further establish the
mechanism of cell death, we performed a well-established apoptosis assay using
double staining for annexin-V FITC (AV) and propidium Iodide (PI) and compared the
cell death caused by oleocanthal to the known apoptosis inducer staurosporine in MDAMB-231 breast cancer cells (Figure 2.1.C) and in PC3 prostate cancer cells (Figure
2.1.D). Whereas staurosporine treated cells single-stained for AV, a hallmark of
12

apoptosis, the oleocanthal treated cells double stained for both AV and PI – clearly
distinguishing the cell death induced by oleocanthal from the apoptotic death induced by
staurosporine. In the literature, double staining by PI and AV is interpreted as necrosis –
although there are occasional apoptotic phenotypes observed (31). The distinction
depends on whether there is an earlier time point where cells are still not permeable to
PI but already stain for AV. In our hands, regardless of how short of a treatment we
performed, including a 15 min treatment, we never observed oleocanthal treated cells to
be single stained for AV, indicating that they do not undergo classic apoptosis. We
always observed double staining for both AV and PI upon oleocanthal treatment, which
led us to conclude that the mode of death was predominantly necrosis.
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Figure 2.1: Oleocanthal induces rapid necrotic cell death in a variety of cancer cells. (A)
The indicated cell lines were treated with 20 oleocanthal for 24 hours and viability was
measured via the reduction of XTT. **P < 0.01 (One-way ANOVA). (B) PC3 cells were treated
with 20 µM oleocanthal or DMSO control for either 24 hours without media change, or 1 hour
followed by a media change into drug-free full growth medium. Viability was measured 24 hours
14

post treatment via the reduction of XTT. (C and D) MDA-MB-231 cells (C) and PC3 cells (D)
were treated with vehicle only (DMSO), or 20 µM oleocanthal for the indicated time points, and
double-stained with AV and PI. Fluorescence was measured on a flow cytometer (MoxiGo II).
Treatment with 1 µM Staurosporine (St) for 4 hours is presented as a positive control for
apoptotic cells. Representative scatter plots from 3 independent experiments are shown, as well
as bar graph quantifications: the lower right quadrant (early apoptosis) is shown in green, and
upper quadrants (necrosis) is shown in red. Bar graphs represent the mean ± SEM (n=3).

Oleocanthal induces LMP and cathepsin release to the cytosol
In the last few years there has been a growing appreciation for the importance of
lysosome-dependent cell death (32), and with this appreciation new techniques and
assays have been introduced to assess LMP. The galectin translocation assay, first
described by Aits et al. (33), is emerging as a gold standard to identify and quantify
LMP. Galectins are β-galactoside binding proteins that normally localize to the cytosol
and feature a diffuse cytosolic staining when observed in a confocal microscope. Upon
damage to the lysosomal membrane, galectins translocate to damaged lysosomes and
get trapped because of their affinity to luminal lysosomal β-galactoside sugars (33, 34).
We performed the galectin translocation assay on MCF7 human breast cancer
cells, as indicated by Aits et al., because of the high levels of galectin-3 in these cells
(33, 34). We used the well-described LMP inducer, L-leucyl-L-leucine methyl ester
(LLOMe) as a positive control. Within 2 hours of treatment with oleocanthal, we
observed robust lysosomal staining for galectin-3, similar to LLOMe treatment (the
positive control) and unlike treatment with vehicle only (DMSO) (Figure 2.2.A). The
translocation of galectin-3 from diffuse cytosolic staining to strong punctate perinuclear
staining is indicative of damaged lysosomal membranes (34).
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We further looked at the integrity of the lysosomal compartment by performing a
LysoTracker retention assay. LysoTracker is a fluorescent acidotropic probe for labeling
and tracking acidic organelles in live cells. In healthy cells, staining with LysoTracker
results in a strong fluorescence signal. Loss of fluorescence is associated with either
damage or de-acidification of lysosomes (35). Known LMP inducers such as LLOMe
lead to decreased LysoTracker fluorescence signal within a short time post-treatment
(36). We, therefore, treated PC3 prostate cancer cells with OC, LLOMe, or vehicle only,
and stained with LysoTracker green. Oleocanthal induced a sharp reduction in
fluorescence intensity (Figure 2.2.B). Although LLOMe treated cells showed a more
pronounced reduction in fluorescence intensity, oleocanthal’s effect was highly
significant and further implicates LMP as the immediate cause of death in cancer cells
induced by oleocanthal.
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Figure 2.2: Oleocanthal induces LMP and cathepsin leakage. (A) MCF7 cells were treated
with DMSO, 30 µM oleocanthal for 2 hours, or 2 mM LLOMe and stained for Galectin-3. Nuclei
were labeled with Hoechst 33,342. Scale bars 20 µm. Green Galectin punctea indicate
compromised lysosomes. (B) PC3 cells were treated with 20 µM oleocanthal for one hour, or
2mM LLOMe for 15 minutes, then loaded with Lysotracker green. Fluorescence intensity was
measured via flow cytometry. Histogram shows a representative shift in Lysotracker
fluorescence associated with perturbation to the lysosomal compartment. Bar graph shows
mean fluorescence intensity of three replicate experiments. (C) PC3 cells were treated with 20
µM Oleocanthal, and two hours later their cytosolic fractions (Cyto), and light membrane
fractions containing lysosomes (Lyso) were separated. Level of cathepsin B (CTSB) and
cathepsin D (CTSD) in the various fractions or whole cell lysates is shown. LAMP2 is a
lysosomal marker and GAPDH is a cytosolic marker. (D) Lysosomes isolated from overnight
17

serum-deprived PC3 cells were incubated for 20 min with the indicated concentrations of
oleocanthal or vehicle (DMSO). At the end of the incubation, lysosomes were filtered through a
vacuum manifold and b-hexosaminidase activity was measured in the flow through and in the
total lysosomal fraction. Broken lysosomes were calculated as the percentage of total lysosomal
hexosaminidase activity detected in the flow-through and plotted in logarithmic scale. (E) PC3
cells were infected with HSP70-1 Lentiviral Activation Particles, or control (scrambled) particles,
and treated with 20 µM oleocanthal for 24 hours.Viability was assayed using reduction of XTT.
*P < 0.05, **P < 0.01 (Two-tailed unpaired t-test). Bar graphs represent the mean ± SEM (n=3).

To further test whether the observed damage to lysosomes was a result of loss
of acidity or actual permeability of the membrane and to assess the functional
consequences of damage to lysosomes, we looked at the distribution of lysosomal
enzymes in the cell. Prior to oleocanthal treatment, lysosomal hydrolases such as
cathepsin B and cathepsin D were entirely excluded from the cellular cytosol (Figure
2.2.C, 2nd lane). Upon oleocanthal treatment, however, we observed a substantial
release of these proteases to the cytosol (Figure 2.2.C, 5th lane), indicating that
oleocanthal treatment causes cathepsins to be released from the lysosomes to the
cytosol.
Interestingly, incubating purified lysosomes isolated from PC3 cells in vitro with
increasing concentrations of oleocanthal (as we don’t know the final cytosolic
concentration of oleocanthal inside cells) had no appreciable difference in lysosomal
stability as compared to vehicle (Figure 2.2.D). This indicates that oleocanthal does not
act directly as a membrane disrupting agent on lysosomes, but rather induces
lysosomal permeability only in a cellular context – likely through oleocanthal
metabolites.
The heat shock protein HSP70 is known to stabilize lysosomal membranes (30)
and in various models of LMP, HSP70 provides protection from subsequent cell death
18

(37). We, therefore, overexpressed HSP70 in PC3 prostate cancer cells and examined
the effect on oleocanthal-induced loss of cell viability. Indeed, oleocanthal-induced loss
of cell viability was partially rescued by HSP70 overexpression (Figure 2.2.E), further
supporting a role for LMP as the cause of oleocanthal-induced cell viability.
Collectively, the data provided in Figure 2.2. strongly suggest that oleocanthal
triggers rapid damage to lysosomes, which causes them to become permeable and
leaky, allowing cytosolic proteins into the lysosome (galectin-3) and lysosomal proteins
(cathepsins) out into the cytosol. The rapid assault on lysosomes, on which cancer cells
are highly metabolically dependent, supports the idea that the cellular toxicity caused by
oleocanthal is due to LMP. All other observed effects of oleocanthal on apoptotic and
necrotic forms of cell death in cancer cells are likely down-stream of the LMP and
dependent on the corresponding degree of LMP.

Oleocanthal induces minimal LMP in MCF10A cells
It is well known that oleocanthal does not affect non-cancer cells as adversely as cancer
cells (14-17, 21, 22). Indeed, a 3-fold higher dose of oleocanthal was required to
achieve the same loss in viability in MCF10A cells compared to cancer cells (Figure
2.3.A and Figure 2.1.A). We checked whether oleocanthal still induces LMP in those
cells. Using the galectin translocation assay, we observed that only a small subset of
MCF10A cells undergoes LMP, and in each one of these cells, only a few lysosomes
seem to be affected (Figure 2.3.B). Furthermore, no appreciable level of cathepsin B or
cathepsin D was found in the cytosol of MCF10A cells as a result of oleocanthal
treatment (Figure 2.3.C). It is unclear whether this is because the MCF10A cells have
less lysosomes, or their lysosomes are less fragile, but these results are in in line with
19

current understanding that non-cancerous cells are less susceptible to lysosome
dependent cell death mechanisms (25).

Figure 2.3: Oleocanthal induces minimal LMP in MCF10A cells. (A) MCF10A cells were
treated with increasing concentration of oleocanthal for 24 hours and viability was measured via
the reduction of XTT. (B) MCF10A cells were treated with DMSO, 30 µM oleocanthal for 2
hours, or 2 mM LLOMe and stained for Galectin-3. Nuclei were labeled with Hoechst 33,342.
Scale bars 20 µm. Green Galectin puncta, and white arrowheads indicate compromised
lysosomes. (C) MCF10A cells were treated with 20 µM Oleocanthal, and two hours later their
cytosolic fractions (Cyto), and light membrane fractions containing lysosomes (Lyso) were
separated. Level of cathepsin B (CTSB) and cathepsin D (CTSD) in the various fractions or
whole cell lysates is shown.
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Oleocanthal extends the life span of mice bearing PNETs
To assess the benefit of oleocanthal treatment in a genetically engineered mouse model
of PNET, RIP-Tag or RIP-Tag; RIP-tva mice (38), we performed a survival trial. The
RIP-Tag mice inevitably develop pancreatic neuroendocrine tumors that progress
through well-defined stages that closely mimic those found in human tumorigenesis
(i.e., hyperplasia, angiogenesis, adenoma, and invasive carcinoma) (38). We treated
mice with 5 mg/kg oleocanthal or DMSO vehicle daily through intraperitoneal injection
starting at 9 weeks of age. The median survival of vehicle-treated mice was 14 weeks of
age (Figure 2.4.A). In contrast, the oleocanthal-treated animals had a significant
extension of life surviving a median period of 18 weeks – or an additional 4 weeks. To
determine the effect of oleocanthal on tumor sizes, we treated another cohort of mice
with 5 mg/kg oleocanthal or vehicle DMSO daily through intraperitoneal injection starting
at 9 weeks of age and euthanized them at 14 weeks of age (5 week treatment).
Although the effect on tumor burden did not reach statistical significance, there was a
trend toward smaller tumor burden with oleocanthal treatment (oleocanthal: 14.7 mm3
vs. DMSO: 24.8 mm3) (Figure 2.4.B).
To determine whether the tumors were smaller due to LMP induced cell death,
we checked for cytosolic cathepsin release in the murine cells. We treated an
established cell line (N134) derived from a PNET tumor from a RIP-Tag; RIP-tva mouse
in vitro and found cathepsin L, a highly expressed cathepsin in N134 cells, present in
the cytosol upon oleocanthal treatment (Figure 2.4.C). The data presented in Figure 2.4.
provide evidence that oleocanthal suppresses tumorigenesis in a mouse model for
PNETs.
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Figure 2.4: Oleocanthal increases life span of mice with PNETs. (A) Kaplan-Meier survival
curve for RIP-Tag mice receiving DMSO or oleocanthal. The mice were treated with DMSO (n=
11) or oleocanthal (5 mg/kg, n=15), 7 days a week. Mice were treated starting from 9 weeks of
age. Both the Gehan-Breslow-Wilcoxon method and the Log-rank (Mantel-Cox) method were
used to calculate statistical significance *P < 0.05. (B) Tumor burden from mice treated with
DMSO or oleocanthal (n =7 for each group) starting from 9 weeks of age and ending at 14
weeks of age. ns P > 0.05. (C) A cell-line derived from a murine PNET, was established (N134).
Cells were treated with DMSO or oleocanthal and analyzed for cytosolic cathepsin L (CTSL) via
Western blot as in Figure 2.2.C.
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Oleocanthal-rich EVOOs are toxic to cancer cells via LMP
The use of EVOO in the Mediterranean diet has been associated with cancer protective
effects (4). However, the concentration of oleocanthal in EVOOs varies greatly (39).
We, therefore, examined the effect of EVOOs with varying oleocanthal concentrations
on cancer cell viability. We hypothesized that EVOOs with high levels of oleocanthal will
show greater toxicity towards cancer cells than EVOOs with lower levels of oleocanthal.
The levels of oleocanthal present in several EVOOs, a non-virgin olive oil, and corn oil
were determined by 1H-NMR as described in Materials and Methods (Figure 2.5.A).
Two EVOOs (Colavita EVOO, and Olive Ranch) had average content of OC. Two
EVOOs (The Governor and Atsas) had levels of oleocanthal that was 5 or 6-fold higher
than the other EVOOs. The non-virgin olive oil (Colavita mild) and the corn oil (Mazola)
had no detectable oleocanthal and were used as negative controls. We then prepared
cellular treatment media that consisted of cell culture media and EVOO in a ratio of
25:1. We used this specific ratio because it would make the maximum oleocanthal level
in the treatment media in the 20 µM range for the most potent EVOO. To ensure that
the oleocanthal was transferred to the media, we vortexed the mixture vigorously, in
essence extracting the more polar components (the phenolic content of the oil) into the
media. We then treated PC3 prostate cancer cells (Figure 2.5.B) and MDA-MB-231
breast cancer cells (Figure 2.5.D) with this enriched media.
Strikingly, the ability of the EVOO enriched media to kill the cancer cells was
correlated linearly to the EVOO’s oleocanthal content. The oils with the highest
oleocanthal content reduced cell viability for both PC3 and MDA-MB-231 cells to a
similar degree to that observed in response to purified OC. The oils with the next two
highest oleocanthal concentrations reduced viability in a manner corresponding with
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oleocanthal concentration; and the oils with no measurable amounts of oleocanthal did
not affect cell viability relative to the no-oil negative control treatment. We also analyzed
the ability of EVOO to induce LMP as determined by cathepsin release. As shown in
Figures 6C and 6E, the EVOOs with the highest concentration of oleocanthal induced
cathepsin release and caused leakage of both cathepsin D and B into the cytosol of
PC3 cells (Figure 2.5.C) and MDA-MB-231 cells (Figure 2.5.E). In contrast, the other
oils caused minimal cytosolic cathepsin release - indicating that the oleocanthal content
in EVOOs is a major determinant for EVOO’s cancer-protective properties. These data
demonstrate that oleocanthal is able to exert this beneficial effect when delivered via
whole EVOO and not only in a purified phenolic form. Interestingly, our model for noncancerous cells, MCF10A, were much less sensitive to the oleocanthal containing
EVOO. Viability was only mildly affected even when treated with the high-oleocanthal
EVOO enriched media (Figure 2.5.F).
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Figure 2.5: Oleocanthal-rich olive oils are toxic to cancer cells via lysosomal membrane
permeabilization. (A) Relative oleocanthal concentration in various oils as measured by H1
NMR as described in Materials and Methods. (B, C, and F) PC3 cells (B) and MDA-MB-231
cells (C) or MCF10A cells (F) were treated with 20 µM Oleocanthal, or the specified oils for 24
hours. Viability was measured via the reduction of XTT. (D and E) Cytosolic lysates were
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collected as in Figure 2.2.C and subjected to Western blot analysis of cathepsin B (CTSB) and
cathepsin D (CTSD) in the cytosol. Bar graphs represent the mean ± SEM (n=3)
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CHAPTER 3: DISCUSSION
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Although several groups have demonstrated oleocanthal’s ability to inhibit key
proteins that promote cell growth and survival (12-17, 19, 20), a unifying mechanism for
the specific and irreversible cellular death-inducing properties of oleocanthal has not
been established. In this report, we observed that a transient exposure of cancer cells to
oleocanthal for one hour resulted in the loss of cell viability after 24 hours. Although a
classic apoptotic mechanism has been proposed (13-18, 20), in our hands the rapid cell
death caused by oleocanthal was necrotic. Specifically, viable cells were not observed
to display phosphatidylserine on the outer membrane leaflet as evidenced by staining
with AV, a well-established phase in the apoptotic cascade. Furthermore, using three
different and complementary methods, we demonstrated that oleocanthal-treated cells
undergo LMP. The latest, most robust method to assess LMP is the galectin
translocation assay (34). We observed that oleocanthal treated MCF7 breast cancer
cells showed robust galectin-3 translocation to lysosomes, similar to that observed with
the established LMP inducer LLOMe. In a biochemical assay that checks the leakage of
lysosomal enzymes into the cytosol, we observed a pronounced leakage of both
cathepsin D and cathepsin B to the cytosol in PC3 prostate and MDA-MB-231 breast
cancer cells. The translocation of cathepsins of two different sizes suggests that the
lysosomal membrane undergoes severe and unrepairable permeabilization.
Agents that are known to cause LMP with only minimal cathepsin release, such
as LLMOe (36) enable cells to survive the initial LMP and repair their lysosomal
membrane. Other agents that cause the release of cathepsin B (a small hydrolase) but
not the release of cathepsin D (a larger hydrolase) are often associated with apoptosis
(23). We, therefore, conclude that the degree of lysosomal damage in the case of
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oleocanthal is massive and leads to rapid necrosis in the affected cancer cells with less
and survivable damage to normal cells.
It was previously suggested that many cancer cells are more vulnerable to
attacks on their lysosomes because they have larger and more fragile lysosomes (40)
and are more reliant on lysosomal processes metabolically (29). Furthermore, many
cancer cells upregulate lysosomal biogenesis and lysosomal enzyme turnover (29).
Therefore, once lysosomal enzymes and acids are released into the cytosol en mass,
rapid cell toxicity ensues (41). Indeed, non-cancerous cell lines that we tested, were
less sensitive to the toxic effects of oleocanthal. Specifically, MCF10A cells showed
very little galectin translocation to lysosomes, and no cathepsin translocation to the
cytosol, indicating that only a small subset of lysosomes are affected, and presumably,
this enables the cells to recover with minimal long term damage.
The effect of oleocanthal was observed in both cell culture and a live mouse
model for the development of PNETs (38) where lifespan was extended by 4 weeks
(29%). It has been reported that 2.6 adult mice days are equivalent to one human year
(42). Based on this life-span conversion, oleocanthal might extend life 10.4 years for
PNET cancer patients. Importantly, the cancer cells from the PNETs when put in culture
released cathepsin upon oleocanthal treatment and died rapidly.
In addition to looking into the effects of purified oleocanthal, we were interested
to see if oleocanthal in a more natural form can cause a similar outcome. Since different
olive oils are known to have varied oleocanthal concentrations as a function of their
origin, harvest time, and processing methods (7), we examined several olive oils with
varied concentrations of oleocanthal from very low to very high. For our in vitro
experiments, we used two EVOOs with average low oleocanthal content and two with
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very high oleocanthal content (about 5 times the average), and for our negative control
we used two oils that contained no measurable oleocanthal. Upon treatment of cultured
cancer cells with oil enriched cell culture media we observed that the concentration of
oleocanthal in the oil was directly related to the toxicity of the oils towards cancer cells.
The oils with the high oleocanthal content completely killed the cancer cells in a manner
similar to purified oleocanthal. The oils with the average oleocanthal content, also
reduced viability but to a lesser extent. The non EVOOs with no oleocanthal had no
effect on cell viability. Furthermore, by looking at cytosolic cathepsin release, the
EVOOs mechanism of promoting cancer cell death also involved LMP, similar to the
effects of purified OC. As with the pure oleocanthal treatment, non-cancerous MCF10A
cells were much less affected, even by the treatment with the high-oleocanthal
containing EVOO.
Many studies have linked consumption of EVOO with reduced incidence of
cancer (4), most significantly a randomized trial in which elevated EVOO in the diet led
to a 62% reduction in the incidence of breast cancer in Spain over a 5 year period (5).
Data provided here link the cytotoxic effects of EVOOs to their level of oleocanthal. The
cytotoxic effects were due to the ability of oleocanthal to induce LMP and necrotic cell
death preferentially in cancer cells. Whereas pure oleocanthal in high doses can also
have negative effects on non-cancerous cells, EVOO is considered safe and healthy
and, therefore, could be both preventative as well as a potential treatment – as
indicated by the PREDIMED study (5). Since the apparent target for oleocanthalinduced necrosis is the lysosome, the reason for the elevated sensitivity of cancer cells
to oleocanthal could be due to the increased size and fragility of the lysosomal
compartment of cancer cells (29). If the enlarged fragile lysosomal compartment (24,
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40) is the reason for increased sensitivity to oleocanthal, it is likely that EVOOs with
high oleocanthal could be preventative for many cancers – in addition to reduced breast
cancer as already shown (5). Whether purified oleocanthal could be used
therapeutically remains to be evaluated.
How can one determine whether there are high levels of oleocanthal in an
EVOO? EVOOs with high oleocanthal levels produce a unique stinging sensation in the
back of the throat and not elsewhere in the mouth, as well as eliciting a brief coughing
that has been used to determine the presence of oleocanthal in EVOO (8). Tasting
EVOO for this signature stinging sensation and cough elicitation could allow people to
identify EVOOs with high oleocanthal content without sophisticated equipment. In light
of the results presented in this report, and since EVOOs have been safely used in the
diet for millennia and are associated with good health, we believe that consuming more
EVOO with high oleocanthal content is a prudent dietary approach to cancer prevention
with the caveat that dietary oils convey calories and consequently other caloric sources
will have to yield to avoid obesity.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
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Oleocanthal is a phenolic compound in EVOO that has neuroprotective, antiinflammatory, and anti-tumorigenic properties. We demonstrate here that oleocanthal
preferentially kills cancer cells over non-cancer cells in vitro and shrinks tumors and
extends lifespan of pancreatic tumor prone mice in vivo. The cell death induced by
oleocanthal can be distinguished from apoptotic cell death and involve necrosis caused
by lysosomal membrane permeabilization. We also show that EVOOs with naturally
high oleocanthal content are effective at killing cancer cells, but not non-cancer cells consistent with known preventative effects of EVOOs on human cancer. The study
suggests that oleocnathal-induced lysosome-dependent cell death could be an anticancer therapeutic strategy.
While this work sheds light on oleocanthal’s induced mode of death, there are
still many unanswered questions relating to its mechanisms of action and interactions
with cellular proteins and organelles. It is not clear whether LMP is a primary or
secondary event following oleocanthal treatment. LMP can be triggered via several
known mechanisms. Lysosomotropic detergents are compounds that cross membranes
and remain trapped within the lysosome after protonation, from where they induce LMP
(43). An increase in free-radical levels can also lead to lysosomal membrane
destabilization. Lysosomes contain high concentrations of iron. Peroxides can react with
intra-lysosomal iron and form highly reactive hydroxyl radicals that cause membrane
damage, inducing LMP (44). Over-activation of the lysosomal membrane modifying
enzyme acid sphingomyelinase has also been shown to cause lysosomal membrane
destabilization (45). The activation of calpains, or calcium-activated cysteine proteases,
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has been associated with LMP triggering cell death via the cleavage of several
lysosomal proteins such as Hsp70, and LAMP2 (23, 46). Whether oleocanthal induces
LMP via one of these mechanisms, or one yet to be understood remains to be explored.
Some of the most intriguing results of our research involve the correlation
between the oleocanthal concentrations in EVOO to the oil’s ability to kill cancer cells.
While these observations make sense, it is still left to be determined whether that is the
causative mode of death. Furthermore, we are very interested to know whether this
effect can be replicated in vivo. Our hope is to find clinicians that are interested in this
topic and are willing to look into the effects of high oleocanthal EVOO consumption in
cancer prevention and treatment.
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CHAPTER 5: MATERIALS AND METHODS
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Reagents
Oleocanthal extracted from EVOO was obtained from Dr. Alexios-Leandros Skaltsounis
at the University of Athens, Department of Pharmacology. The structure and purity
(97%) of the oleocanthal was determined by HPLC and H1 NMR analysis. The
Governor premium EVOO limited edition (Corfu, Greece) and Atsas EVOO (Cyprus)
were a gift from the producers. California Olive RanchTM EVOO (California, USA),
Colavita mild olive oil (Italy), Colavita EVOO (Italy), and Mazola corn oil (USA) were
purchased at a New York City grocery store. All treatments used EVOO from newly
opened bottles that were kept in the dark at room temperature within one month of
opening. oleocanthal concentration was determined by H1 NMR analysis by a third
party (Numega Labs, San Diego, California). All other reagents, unless noted otherwise,
were purchased from Fisher Scientific.

Cells and cell culture conditions
PC3, MDA-MB-231, MCF7, HEK-293T, MCF10A, and BJ-hTert cells used in this study
were obtained from the American Type Tissue Culture Collection. Mouse PNET N134
cells were generated by the Du laboratory(47). PC3 cells were maintained in F-12K
medium, MCF10A cells were maintained in MEGM Mammary Epithelial Cell Growth
Medium Bullet Kit (Lonza) supplemented with 100 ng/ml cholera toxin. Other cells were
maintained in Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 10%, or
15% (N134) fetal bovine serum (Hyclone). No further authentication was performed.
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Antibodies
Mouse anti human galectin-3 antibody (BD Bioscineces, 556904), goat anti-human
Cathepsin B antibody (R&D systems AF953), goat anti human cathepsin-D antibody
(Santa Cruz sc-6486), goat anti mouse Cathepsin L antibody (R&D systems AF1515),
mouse-anti human LAMP2 antibody (abcam 25631), rat anti-mouse Lamp2 antibody
(Hybridoma bank 1B4D), rabbit anti-GAPDH antibody (Cell signaling 2118S), rabbit antiHSP70 antibody (Proteintech 10995).

Cell viability
(2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) (XTT)
reduction assay was used to measure cells viability. In brief, 5×104 cells/500 μl/well
were seeded into 24-well plates in triplicates. After 24 hours, cells were given treatment
medium containing 20 μM OC, or vehicle only and incubated at 37˚C with 5% CO2.
After a 24 h incubation period, cells were treated with 150 μl XTT (Invitrogen™
Molecular Probes™ XTT cat. no. x6493) for 2 h. Then, plates were read at 480 nm
wavelength by a spectrophotometer (Molecular devices, SpectraMax i3). After
subtracting blank well absorbance, the absorbance of vehicle treated cells was set to
100%, and the relative absorbance of oleocanthal treated cells was reported as %
viable cells.

Lentiviral-based overexpression of HSP70
PC3 cells were transduced with either HSP70-1 (Santa Cruz biotechnology sc-418088LAC) or control (Santa Cruz biotechnology sc-437282) lentiviral CRISPR activation
particles per manufacturer protocol. Stable cell lines of HSP70 overexpressing and
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mock transduced control cells were generated via antibiotic selection. Viability assay
was performed as described above.

 -hexosaminidase latency assay

To determine a possible direct effect of oleocanthal in lysosome stability release of bhexosaminidase from lysosomes were used. Briefly, fractions highly enriched in
lysosomes were incubated with oleocanthal and at the end of the incubation lysosomes
were separated from the incubating media by filtration through a 96-well plate with 0.22
μm filter using a vacuum manifold. β-hexosaminidase activity in the media was
measured using a colorimetric assay as described before (48). Broken lysosomes were
calculated as the percentage of total lysosomal hexosaminidase activity detected in the
flow-through.

NMR analyses
Oleocanthal content in oil was assessed via H-1 NMR as previously described (39).
Briefly, oil samples (240 ± 20 mg) and Syringaldehyde internal standard were dissolved
in 0.6 ml of CDC13. H1 NMR experiments (NS=512) were recorded on Bruker AV500.
Proton signals of aldehydes from oleocanthal (9.18 ppm) and Syringaldehyde (9.77
ppm) were integrated.

Apoptosis / Necrosis assay
Mode of death was detected by flow cytometric analysis of annexin V-FITC and
propidium Iodide staining (Vibrant apoptosis assay), Molecular Probes V-13242) per
manufacturer’s protocol.
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Immunohistochemistry
The Aits, Jaattela, and Nylandsted protocol for detection of damaged lysosomes by
Galectin-3 translocation was performed as previously described (33, 34). Slides were
visualized on confocal microscope (Nikon Instruments A1 Confocal Laser Microscope
Series equipped with NIS-Elements acquisition Software).

LysoTracker assay
2.5x105 cells per well were grown in a 6 well plates. The next day, the media was
changed and cells were incubated with treatment media containing 20 µM OC, 2 mM
LLOMe, or DMSO for the indicated amounts of time. In the last 15 minutes of the
treatment, 50 nM LysoTracker green (Invitrogen™ Molecular Probes™ LysoTracker™
green DND-26 L7526) was added to the media. Cells were harvested with trypsin
EDTA, and re-suspended to 1 × 106 cells/ml. Green fluorescent intensity was
immediately analyzed by flow-cytometry (Orflo MoxiGo II).

Cell fractionation and western blot analysis
Cytosolic and light membrane fractions containing lysosomes were obtained using a cell
fractionation kit (Abcam ab109719) and procedure was carried according to
manufacturer’s protocol. Where indicated, highly purified lysosome enriched fractions
were isolated through centrifugation in discontinuous gradients of metrizamide and
Percoll as previously described. Cytosolic and light membrane fractions were obtained
and protein concentration was estimated. Twenty micrograms of proteins were loaded
into wells of freshly prepared polyacrylamide gel. Proteins were electrophoresed and
transferred to a nitrocellulose membrane. The membranes were blocked in 5% milk in
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PBST and incubated overnight with indicated antibodies. The membranes were washed
and incubated with the appropriate secondary antibodies for one hour at RT, washed
again and visualized using KwikQuantTM Imager (Kindle Biosciences).

Oleocanthal administration to animals
5 mg of oleocanthal was dissolved in DMSO to prepare a stock solution of 50 µg/µl.
The stock solution was aliquoted to avoid multiple freeze-thaw cycles, and stored at 20oC. RIP-Tag mice were intraperitoneally injected with DMSO or oleocanthal (5 mg/kg)
daily starting at 9 weeks of age. Mice were weighted weekly starting from 9 weeks of
age to calculate how much working solution (2.5 µg/µl) to make in normal 0.9% saline
and the same dose was used for that week. Mice were euthanized with a lethal dose of
CO2 at a pre-defined humane endpoint. Specific criteria for the endpoint included:
altered respiration, poor grooming, hunched posture, emaciation, 10% weight loss, and
lethargy. Mice were monitored daily by well-trained staff and there were no unexpected
deaths. A lethal dose of CO2 is the methods of euthanasia recommended by the WCM
IACUC and is consistent with the recommendations of the Panel on Euthanasia of the
American Veterinary Medical Association. GraphPad Prism was used for statistical
analysis. Tumor volume (v) was calculated using the formula for a spheroid: v = 0.52 x
(width)2 x (length). All the tumor volumes from each mouse were summed up as the
tumor burden. There was no noticeable influence of sex on the results of this study (p
value > 0.05). This study was carried out in strict accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health. The protocol (2010-0060) was approved by Institutional Animal Care and Use
Committee, WCM. All efforts were made to minimize suffering.
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Oil treatments
Olive oil (or Corn oil) containing treatment media was freshly prepared before each
experiment by mixing oil in serum free media in a 1:25 ratio (1 mL of oil in 24 mL
Media). The mixture was vigorously vortexed on highest setting for one minute on a
tabletop vortex (Scientific industries Vortex Genie-2) to allow the more hydrophilic
components of the oil to be extracted into the aqueous medium. The treatment media
was then allowed to rest for 5 minutes and the oil settled on the top of the tube. The
resulting EVOO enriched treatment media was then collected from underneath the oil
layer and was used to treat the cells.
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